# Protaryx Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/protaryx-medical

- Industry: Medical Devices & Equipment
- Headquarters: Baltimore, US
- Website: www.protaryx.com
- Total disclosed funding: $5.1M
- Latest round: Series A (Jun 30, 2020)
- Investors on record: 2

## About

Protaryx Medical Inc. is a medical technology firm focused on creating innovative access devices for minimally invasive cardiac procedures, particularly enhancing transseptal access in interventional cardiology.Founded in 2019 and headquartered in Baltimore, US, Protaryx Medical Inc. specializes in developing transseptal access devices. The company has secured funding through 3 deals, with the latest being a Seed round on June 30, 2020, raising USD 3.2 mn, contributing to a total raised amount of USD 5.1 mn. David Mester is the CEO.Protaryx Medical specializes in the development of innovative transseptal access devices designed to facilitate the crossing of the atrial septum in the heart. The core product, designed for transcatheter transseptal procedures, aims to enhance workflow efficiency and support catheter-based, minimally invasive left heart interventional therapies. Key features of this device include zero exchange compatibility for left atrial therapy devices, high echogenicity for improved visibility during procedures, and an extendable atraumatic positioning fossa probe. The company's proprietary RF guidewire complements the device, ensuring compatibility with commonly used electrosurgical generators. Protaryx Medical primarily targets healthcare providers and cardiovascular professionals in North America and Europe, aiming to optimize interventional cardiology practices and improve patient outcomes.Protaryx Medical's revenue model is predicated on direct sales of their transseptal access device and associated products to healthcare institutions, including hospitals and specialized cardiac centers. The company engages in B2B transactions, establishing partnerships with medical distributors and device manufacturers to enhance market penetration and accessibility. While specific pricing plans for their flagship products are not disclosed, the structure typically revolves around bulk purchase agreements or individual unit sales tailored to the needs of healthcare facilities. This approach allows for flexibility in addressing varying demand levels while ensuring that healthcare providers have the tools necessary for effective interventions in left heart therapies.Protaryx Medical plans to utilize the recent Seed funding raised in June 2020 to advance the development of new transseptal access devices, targeting a release in upcoming years. The company is also focused on expanding its reach into European markets, aiming to establish a stronger presence by the end of 2023. The funding will support research and development initiatives, ensuring that Protaryx Medical continues to innovate and meet the evolving needs of the interventional cardiology field.

## Funding rounds

- Series A, Jun 30, 2020, $5.1M — UM Ventures, Ajax Health

## Investors

- UM Ventures (https://capitalatlas.ai/funds/um-ventures) — Series A
- Ajax Health — Series A